We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Simple and Inexpensive Ebola Virus Disease Test Developed

By LabMedica International staff writers
Posted on 21 May 2019
Image: A digitally colorized, transmission electron microscopic (TEM) image, which reveals some of the ultrastructural morphology displayed by an Ebola virus virion (Photo courtesy of Cynthia Goldsmith / CDC).
Image: A digitally colorized, transmission electron microscopic (TEM) image, which reveals some of the ultrastructural morphology displayed by an Ebola virus virion (Photo courtesy of Cynthia Goldsmith / CDC).
Ebola and Marburg viruses can cause severe bleeding and organ failure, with fatality rates reaching 90% in some outbreaks. The diseases spread through direct contact with bodily fluids of an infected person, monkey, gorilla, chimpanzee or bat.

Early symptoms of Ebola and Marburg, include fever, headache and diarrhea, and mimic more common diseases, so there's a critical need for a rapid diagnostic test. Such a test could help in efforts to limit outbreaks by quickly quarantining infected persons. But existing diagnostic tests either are inaccurate or are expensive and require extensive training to administer.

Scientists at the Loyola University Health System (Maywood, IL, USA) have generated a panel of mouse single-chain Fv-antibodies (scFvs) to filovirus glycoproteins (GPs) using cell-free ribosome display and determined their cross-reactivity profiles to all known filovirus species. Antibodies could be the key to diagnosing Ebola and Marburg viruses. An antibody is a Y-shaped protein made by the immune system. When a virus or other pathogen invades the body, antibodies mark it for the immune system to destroy.

The team used a technology called cell-free ribosome display, and generated two synthetic antibodies that bind to all six Ebola and Marburg viruses. The study involved the use of non-hazardous proteins that sit on the surface of Ebola and Marburg viruses. Because the actual viruses were not used in the study, there was no risk of infection to the scientists or the public. The antibodies, which are inexpensive to produce, potentially could be used in a simple filter paper test to detect Ebola virus and the related Marburg virus. If the filter paper turns color, the virus is present. The study was published on May 6, 2019, in the American Journal of Tropical Medicine & Hygiene.

Related Links:
Loyola University Health System

Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Electrolyte Analyzer
CBS-4000 (CBS-400)
HPV Molecular Test
BD Onclarity HPV Assay

Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
ADLM